The US Regulator has approved Merck’s COVID-19 at-home antiviral pill

The US Food and Drug Administration has approved Merck's COVID-19 at-home antiviral pill
Merck's newly approved COVID-19 pill has been shown to reduce hospitalisations and deaths by about 3...

US health regulators have approved a second COVID-19 antiviral pill, providing yet another easy-to-use treatment to combat the rising tide of Omicron infections.

Merck’s molnupiravir was approved by the US Food and Drug Administration on Thursday. The approval comes just one day after the FDA cleared Pfizer’s competing drug. Because of its superior benefits and milder side effects, that pill, Paxlovid, is likely to become the first-choice treatment for the virus.

 

In a clinical trial of high-risk individuals early in the course of the illness, Merck’s drug was shown to reduce hospitalizations and deaths by about 30%. The oral drug has been approved by the FDA for the treatment of mild-to-moderate COVID-19 in adults who are at risk of developing severe disease and for whom no other coronavirus treatments are available or clinically appropriate.

 

Molnupiravir’s ability to prevent severe COVID-19 is much lower than previously thought, and the drug label will include a warning about serious side effects, including the risk of birth defects.

 

The Pfizer pill works differently and has fewer side effects. In addition, Pfizer’s drug was three times more effective in testing than Merck’s, reducing hospitalization and death in high-risk patients by nearly 90%.

 

Both the Merck and Pfizer pills, on the other hand, could be promising tools for COVID-19 patients, particularly in the face of the fast-spreading Omicron variant, which is now dominant in the United States and beyond.

 

“It’s critical to expand the country’s arsenal of COVID-19 therapies using emergency use authorization as new virus variants emerge,” said Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research.

 

Antiviral pills, such as Merck’s, are unlikely to be effective against Omicron because they don’t target the spike protein, which contains the majority of the variant’s dangerous mutations.

 

Molnupiravir, a Merck drug, is not approved for use in patients under the age of 18 because it can affect bone and cartilage growth, according to the FDA. Pfizer’s drug was approved for people aged 12 and up on Wednesday.

 

The deal with Merck for up to 5 million courses of molnupiravir at a price of $700 per course compares to the US government’s contract for 10 million courses of the Pfizer drug at a price of $530 per course.

 

Patients in the United States will be able to receive both treatments for free.

 

Merck’s drug slows the coronavirus’s reproduction by inserting small errors into its genetic code. Concerns have been raised that the drug could cause mutations in human fetuses and even lead to more virulent strains of the virus as a result of this genetic effect. The variant risk, however, is largely theoretical, according to FDA scientists, because people take the drug for such a short period of time.

 

Some experts doubt that the Merck drug will play a significant role in the United States.

 

“I don’t think it will be used to the extent that there is an ample supply of Pfizer’s pill,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason given the lower efficacy and increased risk of side effects.”

 

Merck’s senior vice president of clinical research, Dr. Nick Kartsonis, said the company’s scientists are still studying the drug and hope to get it approved for use in children in the future.

 

The molnupiravir restrictions were expected after an FDA advisory panel narrowly endorsed the drug last month, warning that its use would have to be tailored to patients who would benefit the most.

Read more on:

About Robert Oluoch

My focus is economic, politics, entertainment and gaming reviews. My aim is to depict the complication of life through the combination of words and creativity.

Have a tip we should know? tips@rhd.news

Most Read

  1. ARTS
    With a Vengeance and no Apologies, Art Basel Miami Beach Has Returned
    6 months ago
  2. Food
    Is Faux Turkey Finally Vegan-Approved for Thanksgiving?
    6 months ago
  3. News
    Pandora Papers Financial Leak Shows Us the Secrets of the World’s Rich and Powerful
    8 months ago
  4. Health
    US Supreme Court Rejects J & J TALC Cancer Case Appeal
    12 months ago
  5. Lifestyle
    9 Habits that Drain your Daily Focus and How to Avoid Them
    12 months ago
  6. BUSINESS
    Women’s Demand for Shapewear – the big Trends
    1 year ago
  7. BUSINESS
    Valentino Launches its Cosmetics Line
    1 year ago
  8. Business
    McDonald’s Sales Increase Amid COVID Restrictions
    1 year ago
  9. Health
    US Promises to Share 60 million Doses of AstraZeneca Vaccines
    1 year ago
  10. coronavirus
    UK Offers Aid Amid Surging COVID-19 Cases in India
    1 year ago
  11. Entertainment
    Nomadland Director Chloé Zhao, Wins the Best Director in 2021 Oscar
    1 year ago
  12. BREAKING NEWS
    Russia ‘plans to take southern Ukraine’ in the Ukraine war
    4 weeks ago
  13. BREAKING NEWS
    Girls’ schools in Afghanistan ordered shut just hours after reopening
    2 months ago
  14. BREAKING NEWS
    Ukraine: Surrogate mothers and parents face impossible choices
    2 months ago
  15. BREAKING NEWS
    Two women killed in Malmö ‘violence’ at a Swedish school
    2 months ago
  16. BREAKING NEWS
    Anonymous: How Hackers are Attempting to Destabilize Putin
    2 months ago
  17. BREAKING NEWS
    Boris Johnson Sparks Outrage Comparing the Ukraine conflict to Brexit
    2 months ago
  18. BREAKING NEWS
    The Big Talk: War crimes and Russia’s invasion of Ukraine
    2 months ago

Follow @rushhourdaily: